MEREO BIOPHARMA GROUP PLC
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $500.0K | $0 | $10.0M | $0 |
| Cost of Revenue | — | — | — | — |
| Gross Profit | — | — | — | — |
| Gross Margin | — | — | — | — |
| Operating Expenses | ||||
| Research & Development | $17.8M | $20.9M | $17.4M | $29.5M |
| SG&A Expense | $23.0M | $26.4M | $18.4M | $26.1M |
| Operating Income | $-40.1M | $-47.4M | $-28.4M | $-54.4M |
| Operating Margin | -8,021.4% | — | -284.2% | — |
| Interest Expense | $255.0K | $1.4M | $2.9M | $4.2M |
| Pretax Income | $-41.9M | $-43.3M | $-30.0M | $-42.9M |
| Income Tax Expense | $0 | $0 | $-532.0K | $-718.0K |
| Net Income | $-41.9M | $-43.3M | $-29.5M | $-42.2M |
| Net Margin | -8,375.6% | — | -294.7% | — |
| EPS (Basic) | $-0.05 | $-0.06 | $-0.04 | $-0.07 |
| EPS (Diluted) | $-0.05 | $-0.06 | $-0.04 | $-0.07 |
| Shares Outstanding (Basic) | 797.1M | 739.6M | 659.5M | 603.2M |
| Shares Outstanding (Diluted) | 797.1M | 739.6M | 659.5M | 603.2M |
| Dividends Per Share | — | — | — | — |